See other companies on Welcome to the Jungle
Owkin
AI-driven precision medicine
- 201-500 employees
- Healthcare
- B2B
- Artificial Intelligence
- MedTech
- Greenwich Village, New York, NY
Jump to section
Company mission
To connect the global healthcare industry through the safe and responsible use of data and application of AI, for faster and more effective research and drug development.
64% employee growth in 12 months
Our take
Finding the right treatment for patients is essential for saving lives, with some patients reacting differently to drugs and treatments than others with the same health issues. Whilst the analysis of medical data and advice from experts can help healthcare workers pinpoint personalized treatments, accessing such resources is difficult for most biopharma companies and treatment providers.
Owkin provides AI-driven precision medicine services for biopharma companies and treatment providers, leveraging AI to analyze medical data at scale to create interpretable AI assistants for the answering of research questions. These AI assistants are complemented by insights from worldwide and in-house medical experts to inform personalized treatments, novel drug discoveries, and healthcare collaboration.
Whilst the application of AI to medical data analysis is becoming increasingly common in the healthcare industry, Owkin stands out with its approach to designing bespoke AI research assistants driven by human expertise. Through this method, the company claims it can make large datasets of medical records more accessible and interpretable, facilitating personalized medical treatments, medical knowledge collaboration, and novel drug discovery.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Friendly and informal working environment
- Opportunity to work with an international team with high technical and scientific backgrounds
- Flexible work organization and access to remote work
Company values
- Learning - We cultivate a continuous mindset of curiosity, humility, and communication aimed towards improving ourselves, both as individuals and as a collective, and foster the same zeal with partners, customers, and the healthcare community.
Funding (last 2 of 6 rounds)
Jan 2024
$103m
LATE VC
Oct 2022
$124m
SERIES E
Total funding: $567m
This company has top investors
Leadership
Thomas Clozel
(CEO)Experience as Research Fellow for Weill Cornell Medical College. Clinical Assistant Professor for CHU Henri Mondor De Créteil from 2012 to 2014.
Gilles Wainrib
(CSO)Graduated with a PhD in Mathematics and Biology from Ecole Polytechnique in 2010. Assistant Professor for Université Paris 13 Nord from 2011 to 2014, and for École Normale Supérieure from 2014 to 2016.